Novartis (UK)
Industry / private company
Location:
London,
United Kingdom (GB)
ISNI: 000000010642681X
ROR: https://ror.org/039s6n838
Show on Map:
Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer (2025)
O'Shaughnessy J, Tolaney SM, Yardley DA, Hart L, Razavi P, Fasching P, Janni W, et al.
Journal article
Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies (2019)
Coates LC, Wallman JK, McGonagle D, Schett G, McInnes IB, Mease PJ, Rasouliyan L, et al.
Journal article
SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3 (2019)
Coates LC, Mcgonagle D, Schett G, Mease PJ, Quebe-Fehling E, Asquith DL, Rasouliyan L, et al.
Conference contribution
SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3 (2018)
Coates LC, Mcgonagle D, Schett G, Mease PJ, Quebe-Fehling E, Asquith DL, Rasouliyan L, et al.
Conference contribution